Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm, Multicenter II Phase Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma

NCT05236699 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT05236699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05236699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm, Multicenter II Phase Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma
Lead sponsor
Tongji Hospital
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2022
Completion date
January 31, 2025
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholangiocarcinoma